Drug Profile
ARC 183
Latest Information Update: 26 Sep 2005
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Sep 2005 Discontinued - Phase-I for Thrombosis in USA (unspecified route)
- 17 Aug 2005 This programme is still in active development - (BIO-2005)
- 09 Aug 2004 Phase-I clinical trials in Thrombosis in USA (unspecified route)